Warrants Repurchased (and Related Party) |
6 Months Ended | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||
| Warrants Repurchased (and Related Party) | |||||||||||||||||||||||||||||||
| Warrants Repurchased (and Related Party) |
5. Warrants Repurchased (and Related Party) September 2025 Repurchases During September 2025, the Company repurchased and cancelled certain outstanding common stock purchase warrants as follows:
All repurchased warrants were cancelled upon settlement and accounted for as equity transactions with no effect on the condensed consolidated statement of operations. March 2026 Issuance On March 2, 2026, in connection with the Securities Purchase Agreement with First Finance described in Note 10 — Shareholders' Equity, the Company issued warrants to purchase up to 437,500 shares of common stock. The warrants had an exercise price of $5.00 per share and a term of two years, expiring March 2, 2028, and became exercisable six months from the date of issuance. It is a condition to Vivani Medical, Inc.’s obligations to consummate the closing of the Merger Agreement for First Finance to have waived any right to receive value in respect of any warrants held by it or its affiliates. On August 4, 2026, all warrants issued pursuant to the Securities Purchase Agreement were cancelled. See Note 14 — Subsequent Events. March 2026 Repurchase On March 9, 2026, the Company entered into a Warrant Repurchase Agreement with CVI Investments, Inc. pursuant to which the Company repurchased outstanding common stock purchase warrants originally issued on September 12, 2021, exercisable for an aggregate of 24,155 shares of common stock. The Company paid $0.9108 per underlying share, representing an aggregate cash purchase price of $22. Upon settlement, the warrants were cancelled and are of no further force or effect. The repurchase was accounted for as an equity transaction with no effect on the condensed consolidated statements of operations.
Warrants outstanding as of June 30, 2026 consist of (187,202 underlying shares issued in prior financings and 437,500 underlying shares issued on March 2, 2026. The Company issued no warrants and repurchased no warrants during the three months ended June 30, 2026. Related Party The September 2025 repurchase from Edward Dallin Bagley was approved by the Board of Directors in accordance with the Company's related person transaction policy. No amounts were outstanding with Mr. Bagley related to these warrants as of June 30, 2026. |